Virios Therapeutics (NASDAQ: VIRI)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.480 | 0.0500 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Virios Therapeutics (NASDAQ: VIRI) through any online brokerage.
Other companies in Virios Therapeutics’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Acurx Pharmaceuticals (NASDAQ:ACXP), Synaptogenix (NASDAQ:SNPX), Celyad Oncology (NASDAQ:CYAD) and Brooklyn (NASDAQ:BTX).
The latest price target for Virios Therapeutics (NASDAQ: VIRI) was reported by HC Wainwright & Co. on Wednesday, December 15, 2021. The analyst firm set a price target for 12.00 expecting VIRI to rise to within 12 months (a possible 173.35% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Virios Therapeutics (NASDAQ: VIRI) is $4.39 last updated June 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for Virios Therapeutics.
Virios Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Virios Therapeutics.
Virios Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.